Trial Profile
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Biomarker; Therapeutic Use
- 19 Jan 2010 Primary endpoint 'Mayo score' has been met.
- 19 Jan 2010 Status changed from active, no longer recruiting to completed according to results published in The American Journal of Gastroenterology.
- 19 Jan 2010 Results have been published in The American Journal of Gastroenterology.